SAN DIEGO, February 8, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [i]

"People affected by EB suffer skin blisters and almost constant, acute pain and scarring," said the study's Principal Investigator, H. Alan Arbuckle, MD, Section Head Pediatric Dermatology Kaiser Permanente Colorado, Wound Care Consultant, Epidermolysis Bullosa Center of Excellence, The Children's Hospital, Aurora Colorado. "The current standard of care is daily wound care, bandaging and pain management. I am excited to be involved in testing the efficacy and safety of ABH001 as a potential treatment option for these patients."

ABH001 for EB has been granted an orphan drug designation in the US and EU, and has also received Fast Track designation from the US Food and Drug Administration (FDA), which is aimed at facilitating the development and expediting the review of drugs and biologics that fill an unmet medical need. In addition, the European Medicines Agency's Pediatric Committee has agreed on a pediatric investigation plan for ABH001 for the treatment of EB.

The new Phase 3 study is a multi-site, prospective, randomized, open-label, intra-subject controlled trial evaluating the efficacy and safety of ABH001 to initiate healing and reduce the wound surface area of selected stalled, chronic cutaneous wounds associated with generalized EB. Approximately 20 subjects with generalized EB aged three years and older are planned to enroll in the trial, which is targeted to be conducted in 10 to 15 sites across the US, Europe and Canada. The study will comprise ABH001 applications sufficient to cover the surface area of the wound, applied topically every 4 weeks with protocol-specified dressings until healed or for up to 24 weeks.

"We are excited that Shire Regenerative Medicine has launched this trial," said Brett Kopelan, Executive Director of the Dystrophic EB Research Association of America (DebRA ) and father to a 5-year-old girl with recessive dystrophic EB. "While there is currently no cure for EB, I am encouraged that ABH001 istargeting the chronic wounds that are the hallmark of this disease.I applaud Shire for pushing this forward and look forward to working closely with them as the trial progresses."

"We are very eager to begin evaluating ABH001 as a potential wound treatment option for people with EB. We believe it has the potential to initiate and continue wound healing in this patient population," said Jeff Jonas, MD, President of Shire Regenerative Medicine. "We are committed to developing regenerative medicine solutions that enable people with life-altering conditions to lead better lives, and are encouraged by the fast track and orphan drug designations we have received to further develop this potential therapy for people, most often young children, suffering from this devastating condition."

Shire is also developing an intravenous protein replacement therapy for the treatment of dystrophic EB, which the company's Human Genetic Therapies business recently acquired from Lotus Tissue Repair, Inc. Initiation of this pivotal trial of ABH001 for patients with EB further demonstrates Shire's commitment to developing a portfolio of products targeted toward patients who suffer from this disease.

ABH001 is comprised of allogenic neonatal dermal fibroblasts seeded on a poly(glycolide-co-L-lactide) scaffold, and is currently approved and marketed in the United States as a Class III medical device under the trade name Dermagraft for the treatment of diabetic foot ulcers.

About Epidermolysis Bullosa (EB)

Visit link:

Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa

By Carolyn Y. Johnson, Globe Staff

Hundreds of people from hospitals, universities, and industry gathered today at Harvard Medical School to discuss the transformative power of health cares latest buzzword, personalized medicine. But the day began on a combative note.

In a keynote talk at the Personalized Medicine Conference, Dr. Ezekiel Emanuel, an oncologist who previously served as a health policy adviser to the Obama administration, called personalized medicine hype, a myth, and unaffordable.

Emanuel, who conceded this wasnt his area of expertise, argued that medicines goal has always been to better target therapies, whether it is choosing the drug to treat a patients specific infection or making a decision about how to treat a cancer patient based on the characteristics of their disease. He showed a slide with his own back of the envelope analysis of a single genetic test to support his argument that personalized medicine isnt significantly extending life and aint saving a dime.

If thats all it means, big deal. Ho hum. Targeting is nothing new, Emanuel said. I dont think thats a revolution.

Emanuels comments spurred lively discussion and disagreement, as well as evidence that contradicted his arguments, such as a 2009 study that showed using a genetic test to target a colon cancer treatment would reduce health care costs.

I disagree completely with Zeke Emanuel, said Dr. John Mendelsohn, past president of the University of Texas MD Anderson Cancer Center, who discussed that centers expanding efforts in identifying the genetic fingerprints of tumors and targeting treatments.

Dr. John Niederhuber, executive vice president of Inova Health System in Falls Church, Va. said that he agreeed with one key point of Emanuels talk: that personalized medicine was being overhyped, potentially giving patients false hope before the science is ready.

Despite the disagreements, when Emanuel polled the audience about what would be likely to have a larger impact on longevity and reduce medical costs, the audience overwhelmingly voted not for genetic tests or personalized treatments, but for cutting calories, smoking, and other behavioral changes.

Read more:

Conference on future of personalized medicine kicks off with a challenge

Medicine Hat Police vs. Medicine Hat Fire Rock Paper Scissors Showdown!
Medicine Hat Police vs. Medicine Hat Fire Rock Paper Scissors Showdown! 2013

By: mhpsweb1

More:

Medicine Hat Police vs. Medicine Hat Fire Rock Paper Scissors Showdown! - Video

Laid-Back Mystic Hip Hop Instrumental - "Bad Medicine" (Mystic Beat)
Download Over 100 Beats For Free Incl. License: http://www.diractbeats.com Produced by: The Goat (www.thegoatbeats.com) Laid-back mystical rap beat called "Bad Medicine" produced by The Goat of Diract Beats. Use this laid-back mystic hip hop instrumental and all our other hip hop instrumentals for your personal, non-commercial projects. Buy a lease for $19.90 to receive the beat tag-free in hi-quality. Go to our website http://www.diractbeats.com for instant, automated beat delivery and many more beats like this one! Picture by Todd Huffman

By: diractbeatz

Read more from the original source:

Laid-Back Mystic Hip Hop Instrumental - "Bad Medicine" (Mystic Beat) - Video

medicine in the side effects
youtube.com/truthhurtz87 talking about medicine and the side effects people go through

By: samuel yarbrough

Read more here:

medicine in the side effects - Video

The number of sports medicine experts required to improve the standard of sports is desperately lacking in the country, lamented Indian Federation of Sports Medicine president Dr P S M Chandran.

The Sport Authority of India [ Images ] (SAI) has only three sports doctors, two physios, two sports psychologists and one nutritionist for the entire country, Chandran said.

"India needs at least 50 to 60 sports doctors for various national camps only," he said while addressing a seminar on sports medicines.

"Currently, we are having vast shortage of man-power in the form of sports doctors and sports psychologists," the former Chief Medical Officer of Hockey India said.

Stating that sports bodies are also responsible for the scenario, Chandran claimed even the Board of Control for Cricket in India (BCCI), the richest sports body of the country, does not have a qualified sports doctor.

"We do not have an institute to impart courses on sports medicine and science," he said adding former Union Sports Minister Ajay Maken [ Images ] had proposed to set up a National Institute of Sports Science and Medicine, which was placed before the Union Cabinet in September 2011 but no final decision was taken.

He said some universities are offering diploma course in Sports Medicine, besides the National Institute of Sports (NIS), Patiala.

The seminar was organised by the sports department of Tata Steel [ Get Quote ].

Copyright 2013 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.

More here:

'India lacks sports medicine experts'

PHILADELPHPIA John B. Jemmott, PhD, professor of Communication in Psychiatry at the Perelman School of Medicine and Kenneth B. Clark Professor of Communication at the Annenberg School for Communication, has been selected as one of 60 scholars profiled by the National Science Foundations (NSF) Graduate Research Fellowship Program (GRFP).

For over 20 years, Dr. Jemmott has been funded by the National Institutes of Health to conduct research developing and testing the efficacy of theory-based culturally appropriate HIV/STD risk-reduction interventions for a variety of populations in the United States and sub-Saharan Africa.

The list of the top 60 GRFP fellows selected was compiled in honor of the NSFs GRFPs 60th Anniversary. Directorates from across NSF were polled to nominate from among former GRFP recipients over 46,000 in all named since 1952 those GRFP recipients who best reflect the diversity and rich history of the programs. Nominations ranged from junior high school teachers to Nobel laureates. The final candidates were selected based on a range of criteria, including gender, race/ethnicity, field of study, geographic location of graduate institutions, and current place of employment. Other honorees on the list include Federal Reserve Chairman Ben Bernanke and University of Chicago President Matthew Zimmer.

For more information, see the Annenberg School for Communications news release.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Read more here:

Perelman School of Medicine Researcher Honored by the National Science Foundation

Public release date: 7-Feb-2013 [ | E-mail | Share ]

Contact: Christine A. Somosi christine.somosi@case.edu 216-368-6287 Case Western Reserve University

CLEVELAND February 7, 2013 - The Case Western Reserve University School of Medicine has received a $220,000 grant from the DeGregorio Family Foundation to study gastric cancers, which remain among the most deadly forms of disease.

The two-year grant from the foundation, which focuses on stomach and esophageal cancer research and education, will support studies aimed at identifying and developing more effective treatments for gastric and esophageal malignancies.

The grant focuses on interleukin-33 (IL-33), a novel mediator that causes inflammation. That inflammation in turn may be involved in the early events leading to development of gastrointestinal cancers, including gastric cancer. IL-33 is the newest member of the IL-1 family of cytokines, which are specific molecules involved in various disease processes, such as inflammation, autoimmunity, and cancer. Cytokines are produced by many different types of cells and deliver signals that allow cells to communicate with each other.

"We are grateful to the DeGregorio Family Foundation for having chosen to support our project this year and for bringing attention to upper GI malignancies," said Theresa Pizarro, PhD, associate professor of Pathology and Medicine, Case Western Reserve University School of Medicine, and the study's principal investigator. "Using a multi-disciplinary approach, we are hopeful that this research will allow us to study novel pathways that will uncover the potential sequence of events that occur from inflammation in the stomach to gastric cancer, and to generate more specific and targeted treatment modalities for this devastating disease, for which there is currently no cure. The DeGregorio funds will be critical for this mission and to further expand our research program in this important area of investigation."

Dr. Pizarro's expertise is in cytokine biology, focused on the characterization and function of IL-1 family members, and the role they play in inflammation and gastrointestinal diseases.

Li Li, MD, PhD, associate professor of Family Medicine, Epidemiology & Biostatistics and associate director for Prevention Research, Case Comprehensive Cancer Center, Case Western Reserve University, is the co-investigator. Wei Xin, MD, PhD, assistant professor of Pathology, is the collaborator.

Lynn DeGregorio, president of the DeGregorio Family Foundation, based in New York City, said, "The foundation has always sought to fund research that is innovative and will be a catalyst to collaboration. The application from the Case Western Reserve University School of Medicine will increase the depth and breadth of research into these malignancies, and so we were excited to be able to make this award possible."

Pizarro's funded proposal, entitled, "Role of the novel IL-1 family member, IL-33, in the gastritis-metaplasia-carcinoma sequence," was the only proposal of 24 international applicants selected for funding in the third annual DeGregorio Foundation Award for Cancers.

See the original post:

Collaboration and innovation win CWRU School of Medicine grant to study gastric cancer

There is a growing movement to treat animals with the best that human medicine has to offer, including physical therapy, hydro-therapy, and even alternative therapies -- acupuncture, to be precise.

When dog owner Joe Bowerman's beloved Shitzu, Snoot, was suffering from chronic back problems, which is common among the breed, and became paralyzed, Bowerman started looking into acupuncture treatments.

"He couldn't use his back," said Snoot's vet Leilani Alvarez of Animal Medical Center in New York City. "Acupuncture works primarily with the central nervous system, so there really isn't an equivalent conventional medicine."

Watch the full story on "Nightline" tonight at 12:35 a.m. ET

Three million people in the United states use the ancient Chinese therapy for debilitating pain, to help them quit smoking, and more. But at Animal General Hospital, also in New York City, veterinarians are using it extensively for cases like Snoot's.

There, three acupuncture treatments a week cost a $100 a visit.

"You make sacrifices for the things you care about, things that you love," Joe said. "We all do it in a different way. This guy has given me great companionship, and I didn't want to lose him so I made those sacrifices for him."

Delilah's owner Mark Rindler swears that acupuncture made all the difference for the dachshund.

"She has a bad back, a back neck ... and acupuncture saved her life," he said. "We almost had to put her down last August she was in such bad shape. Medicine didn't help."

While animals can't verbalize whether the treatment works or not, their owners said they could see a difference.

Continued here:

Dog-upuncture: Treating Pets With Human Medicine

HARTFORD, Conn.--(BUSINESS WIRE)--

The Tour for Diversity in Medicine, a volunteer program started by two young doctors, will launch its third bus tour the week of February 11, this time traveling to six Texas universities to help minority students pursue careers in medicine and dentistry. Thanks to a grant from the Aetna Foundation, 15 doctors, dentists and medical school students from across the country will travel more than 1,000 miles to provide full-day, hands-on workshops to undergrad students on six different campuses.

The Tour for Diversity in Medicine hopes to help diversify the health care profession by giving minority students the advice and tools theyll need to pursue medical careers. Although African Americans, Hispanics and Native Americans compose more than 26 percent of the U.S. population, they represent only 6 percent of practicing physicians and 5 percent of dentists, according to the Association of American Medical Colleges. In 2011, African-American and Hispanic students made up only 15 percent of all U.S. medical school applicants.1 Yet research shows that patients who receive care from doctors of the same background are more satisfied with their care and more engaged in their treatment.

Not only does todays physician workforce not reflect the growing diversity of our country, but this health equity gap is often most apparent in the at-risk minority communities that need help most. We are trying to make a tangible difference by going directly to students and showing them the changes that they can make for themselves and their communities by considering a career in medicine, said Alden Landry, M.D., co-founder of the Tour for Diversity in Medicine and an emergency department physician at Beth Israel Deaconess Medical Center in Boston. Our tours address the national need for a more diverse physician population at a grassroots levelschool by school and student by student.

The week of February 11, the Tour for Diversity in Medicine will travel to the following universities in Texas:

As the United States becomes more racially and ethnically diverse, our nations health care providers must be able to respond to the wide variety of patient perspectives in order to provide the best possible care, said Gillian Barclay, D.D.S., Dr.PH., the Aetna Foundations vice president and director of national grant making. The Aetna Foundation is pleased to be a founding sponsor of the Tour for Diversity in Medicine and once again support these dedicated doctors as they help achieve more diversity in the next generation of health care providers. Our support for the tours is part of our ongoing work to develop health care leaders from underrepresented communities.

About 150 students from each school are expected to participate in the full-day program. There are sessions on the medical school application process, admissions tests, financial aid, interviewing skills, and an overview of health disparities. Students will interact one-on-one with mentors who will offer personal insights and share their experiences about how to build a successful career in medicine or dentistry.

Were excited to be back on the road and traveling to Texas to reach Hispanic and African-American students. We recognize that many students may not have the resources or information to seek out medical school recruitment fairs on their own, so we come directly to campus to help spark interest in health care careers, said Kameron Matthews, M.D., J.D., co-founder of the Tour for Diversity in Medicine and medical director of the Division Street site of Erie Family Health Center in Chicago. By offering student workshops with doctors who come from similar backgrounds, we are helping students overcome perceived barriers to entering the medical profession and showing them what steps theyll need to take to build a fulfilling career.

Additional support for the Texas Tour comes from the U.S. Army, AAMC, American Association of Colleges of Osteopathic Medicine, and American Dental Education Association. For more information, follow the Tour for Diversity in Medicine on Facebook and Twitter @Tour4Diversity or visit tour4diversity.org.

About the Aetna Foundation

View post:

Tour for Diversity in Medicine and Aetna Foundation Rev Up Third Bus Tour to Mentor Med-School-Bound Minority Students

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that members of the companys management team will present at the following upcoming investor conferences:

About Foundation Medicine

Foundation Medicine, is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical assay, FoundationOneTM, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine is a registered trademark, and FoundationOneTMis a trademark of Foundation Medicine, Inc.

See the article here:

Foundation Medicine to Present at Upcoming Investor Conferences

ATD Season 8 Episode 4 Internal Medicine, Family Medicine, Breast Diseases

By: NETTVCATHOLIC

See original here:

ATD Season 8 Episode 4 Internal Medicine, Family Medicine, Breast Diseases - Video

Nico Rivers - Molotovs and Medicine at Lot 1 Cafe (1/15/13)
Nico Rivers performs "Molotovs and Medicine" at Lot 1 Cafe in Los Angeles, CA

By: Derek Scott

See original here:

Nico Rivers - Molotovs and Medicine at Lot 1 Cafe (1/15/13) - Video

STEPHEN VOSS/REDUX/EYEVINE

In his last role two years ago with the Opera Vivente in Baltimore, Maryland, Christopher Austin played the Calvinist chaplain in Gaetano Donizetti's Lucia di Lammermoor. The story does not lack for drama: the heroine pulls out a knife in her wedding bed and stabs to death the husband who has been forced on her in place of her true love. On the heels of the murder, the chaplain is the guy who is trying to bring order to chaos, says Austin, a bass-baritone who once considered a full-time career in opera.

Austin's most recent stage part has a certain resonance with his new day job. In September, he was appointed as director of the fledgling National Center for Advancing Translational Sciences (NCATS) at the US National Institutes of Health (NIH) in Bethesda, Maryland. In existence since December 2011, the centre has an ambitious some say audacious agenda that channels the central passion of both Austin and his boss, NIH director Francis Collins: to get more successful medicines into more patients, more quickly. That means forcing the agonizingly slow, failure-prone process of 'translational research' the term of art for moving promising discoveries from the lab to the clinic into a higher gear.

Passion runs high among the sceptics, too. Researchers both inside and outside the agency fear that NCATS the first new centre at the NIH in more than a decade, funded at US$575 million last year will encroach on a finite pot of money that they say would be better spent probing the mechanisms of basic biology and disease. Others question the scale of its mission. With the available resources, how are you going to achieve this? asks Thomas Caskey, a molecular geneticist at Baylor College of Medicine in Houston, Texas. To me, you cannot just take this money and be another biotechnology company and you certainly don't have enough money to be a pharmaceutical company.

NCATS will be neither, Austin responds. What will set it apart, he says, is a focus on overcoming obstacles on the road to drug development, from inadequate toxicology methods to inefficient clinical-trial recruitment, rather than actually producing the drugs. In an era in which more than 95% of drug candidates fail, and a novel drug takes 13 years and more than $1 billion to develop, NCATS has to be focused on logarithmic improvements in the process, says Austin. You can't do this in a brute-force way. You have to do it differently. You have to drive the technology development.

Austin's fans say that if anyone has a shot at making this work, it is him. This guy has got clinical training, industry training and scientific training. If you wanted me to pick a quarterback, this is the quarterback I'd pick, says Lee Nadler, director of Harvard Catalyst, the NCATS-funded clinical and translational science centre based at Harvard University in Boston, Massachusetts. But whether quarterback or maestro, Austin has now to give the performance of his career. The biggest risk he faces lies in not delivering something concrete within 1224 months, says Nadler. Everybody is watching him.

Austin learned early, and at first-hand, about the tragic shortcomings of medicine. One night in 1989, when he was a neurology resident on call at Massachusetts General Hospital in Boston, an ambulance brought in a middle-aged man with end-stage amyotrophic lateral sclerosis (ALS), a disease that slowly destroys muscle power but leaves brain function intact. Patients usually die when their breathing muscles give out.

The man had a 'do not resuscitate' order, but, because of a miscommunication, he had been revived by the paramedics. Furious that he had not been allowed to die at home, he demanded that his ventilator be turned off. Austin complied. Watched by his family and Austin, the man died slowly over three hours, in the end turning blue before his heart monitor flatlined. It was like sitting through the crucifixion, Austin recalls. And I just said: 'I can't do this. There has got to be a better way.'

Convinced that he had to do more, Austin began a postdoc in the lab of Connie Cepko, a geneticist at Harvard Medical School in Boston. There, he dived into developmental neurology, using new tracing techniques to reveal the migration of neural progenitor cells in the budding mouse cortex (C. P. Austin and C. L. Cepko Development 110, 713732; 1990).

He was just really driven. He absolutely loves research, says Cepko. She recalls the day that Austin's wife went into labour with the couple's first child at the Brigham and Women's Hospital, around the corner. I went to the lab and there was Chris sitting as his bench, pipetting away. I said, 'Chris, aren't you supposed to be in the delivery room?' He said: 'It'll be a couple hours [yet]'.

Originally posted here:

Translational research: Medicine man

BOCA RATON, FL--(Marketwire - Feb 6, 2013) - Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific electronic medical records (EMR) application, announced today that it has been listed at No. 47 on FORBES' annual ranking of America's Most Promising Companies -- a list of one hundred privately held, high-growth companies with bright futures.

"We are honored to be recognized alongside so many innovators as one of America's Most Promising Companies," said Daniel Cane, Modernizing Medicine's President and CEO. "This has been an incredible year of growth for Modernizing Medicine and to receive this award from one of the world's leading business publications is confirmation that our transformative technology is making its mark on the healthcare industry."

FORBES' list of 'America's Most Promising Companies' features 100 privately held up-and-comers that are poised to grow and change the world with their compelling business models, strong management teams, notable customers, strategic partners and dynamic investors.

For the Most Promising list, FORBES strove for a holistic gauge of young, privately-held companies, trying to pin down their trajectories by looking at a slew of variables. Over the course of six months FORBES reviewed thousands of applications. The final assessment is based on growth (both in sales and hiring), quality of management team and investors, margins, market size and key partnerships. FORBES turned to CB Insights, a Manhattan-based data research firm that specializes in assessing private companies, to refine the search. Their MOSAIC software scans 45,000 sources to measure a company's health. A new distribution deal, for example, marks a positive signal, while the loss of an executive is a negative. MOSAIC gathers those myriad signals into a final score that FORBES uses as an initial guide in producing the list. After verifying sales numbers, speaking with each company and debating their merits and blemishes, FORBES produces a final ranking.

Modernizing Medicine's inclusion on FORBES' list comes at the close of an incredible year for the three-year old company. In 2012, Modernizing Medicine grew its customer base by over 1000%, bringing the total number of providers using EMA to over 2,000. Modernizing Medicine also more than doubled its staff, grew its product line with the addition of EMA Plastic Surgery and closed a $12 million dollar capital raise, with a combination of equity capital and a senior debt bank facility. The company was named the #1 Fastest Growing Company in South Florida by the South Florida Business Journal in its "Fast 50," the #1 "Top Mobile Startup in South Florida" by the South Florida Technology Alliance and was named one of the "2012 Florida Companies to Watch" by the Florida Economic Gardening Institute. Daniel Cane was also recognized as a great leader and innovator with '40 Under 40' awards from the South Florida Business Journal and Enterprise Florida, Inc.

Modernizing Medicine is looking forward to an exciting year, with the launch of EMA Cosmetic, EMA Orthopedics and EMA Otolaryngology.

About Modernizing MedicineModernizing Medicine is delivering the next generation of electronic medical records (EMR) technology for the healthcare industry. Our product, Electronic Medical Assistant (EMA), is a cloud-based specialty-specific EMR with a massive library of built-in medical content, designed to save physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with over 400 different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, optometry and plastic surgery markets, and to more than 750 physician practices across the country.

Read this article:

Modernizing Medicine Is Named One of 'America's Most Promising Companies' by FORBES

By Chelsea Conaboy, Globe Staff

Steward Health Care has proved a game changer for medicine in Massachusetts. The for-profit hospital system formed when private equity firm Cerberus Capital Management two years ago rescued a group of struggling Catholic hospitals, with St. Elizabeths and Carney Hospital at the helm. In Sundays Globe, reporter Robert Weisman took a long look at how Steward Health Care is reshaping medicine in Massachusetts.

Theres a bubbling caldron of change going on in Massachusetts health care, and Steward is the single biggest part of it right now, James Roosevelt Jr., chief executive of Tufts Health Plan, told Weisman.

A recent report from the attorney generals office found that the system has lost tens of millions of dollars. But thats not the whole story, Weisman writes:

Over the past two years, Steward has added to its portfolio by buying four more community hospitals, wooed large groups of doctors from Harvard-affiliated rivals Beth Israel Deaconess and Partners HealthCare, taken over post-acute care provider New England Sinai Hospital in Stoughton, and struck eyebrow-raising pacts to send patients in need of more complex care from its community hospitals to Partners-owned Massachusetts General and Brigham and Womens hospitals in Boston.

But its too early to say whether Stewards model is more economical. The attorney generals report found that while its hospitals are the low-cost providers in some communities, their prices are higher than those of competitors in other locales.

Paul Levy, former chief executive at Beth Israel Deaconess Medical Center, wondered aloud on his blog about how Steward doctors will fair in the long run, as the system signs contracts with Blue Cross Blue Shield of Massachusetts that return to providers a portion of what they save compared to a baseline in medical spending:

One commenter on Weismans story raises an interesting point about whether Stewards model meshes with the new model of health care created under state and federal health laws. Accountable care organizations also are designed to push hospitals and doctors to be more cautious in spending health care dollars by giving them a stake in potential savings.

Reader amirtllr writes on BostonGlobe.com:

Read this article:

Clipboard: How is Steward Health Care shaping medicine in Massachusetts?

TEL AVIV, Israel--(BUSINESS WIRE)--

Compugen Ltd. (CGEN) today announced that the Company was invited to present at the Molecular Medicine Tri-Conference 2013, at Moscone Convention Center in San Francisco, California.

Dr. John Hunter, Vice President, Antibody Research & Development at Compugen, Inc., a wholly owned subsidiary of Compugen Ltd., will participate in a session entitled Cancer Biologics: Approaches Changing the Treatment of Cancer. Dr. Hunter's presentation entitled Predictive Drug Discovery for Novel Cancer Biologics will take place on Thursday, February 14 at 1:45 pm PST. In his talk, Dr. Hunter will demonstrate how Compugen has applied its predictive discovery platforms to identify novel immune checkpoints for targeted antibody immunotherapy in cancer. Validation data for representative targets will also be presented.

About Compugen

Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for thein silico(by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Go here to see the original:

Compugen to Present at the Molecular Medicine Tri-Conference 2013 in San Francisco

FRESNO, Calif. (KFSN) -- Choosing medicine for a cold, flu, and other aches and pains can be overwhelming.

Why is the drug aisle so confusing?

Dr. Marvin Lipman, Consumer Reports Medical Adviser said, "The problem is labels like extra strength, maximum strength, or ultra-strength really have no standard definition."

Take Ultra-Strength Tums. It has 100 percent more of its active ingredient than the regular version.

But Gas-X Ultra-Strength has 125 percent more of its active ingredient.

"The point is you really have to read the label in order to know how much you're taking," Lipman said.

Claims like "all day" and "long acting" are tricky, too. All-day Aleve lasts up to 12 hours. But this all-day medicine lasts 24 hours. With drugs that promise to relieve multiple symptoms, like a cold, flu, and sore throat, you could end up taking something you don't need.

"Drugs that treat multiple symptoms often have more than one ingredient, sometimes many," lipman said.

So if you take another medicine that contains one of those ingredients, you might wind up taking too much.

Consumer reports says best is choosing a single ingredient drug whenever you can, like ibuprofen for aches and pains or acetaminophen for a fever or headache.

Link:

Flu season, cold medicine and confusing labels

ST. LOUIS--(BUSINESS WIRE)--

Certara, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, announced that the Institute of Computational Comparative Medicine (ICCM) at Kansas State University has been named a PhoenixCenter of Excellence.

Certara has developed Phoenix, the leading PK/PD modeling and simulation platform, to support non-compartmental analysis, population PK/PD modeling and simulation, and IVIVC analysis. This partnership will focus on the application, validation and extension of the Phoenix platform to support studies in veterinary medicine, from toxicology to animal health. Dr. Jim Riviere recently formed the Institute of Computational Comparative Medicine (ICCM) to develop unique computational medicine capabilities that will apply to animal studies and to advance the general state of the field.

The work we are focused on could reduce the number of animal studies required for drug approval, said Dr. Jim Riviere, Director of the ICCM. It could improve the determination of withdrawal times of drugs in animals with diseases; it could support the modeling of chemical risk assessment. There are many opportunities to advance veterinary medicine by using modeling and simulation methods combined with experimental data to form a quantitative framework for decision making.

Certara currently has six Phoenix Centers of Excellence that are focused on leveraging Phoenix to support clinical pharmacology and to train the next generation of practitioners, said Dr. Daniel Weiner, Senior Vice President and General Manager of Certara. We are pleased to work with Kansas State University to begin advancing the use of Phoenix to support animal health studies, aimed at both improving animal medicine as well as the reduction of animals used in clinical trials.

About Certara Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development. Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation with scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit http://www.certara.com.

See the rest here:

Certara Establishes the Kansas State University College of Veterinary Medicine as the Latest Phoenix Center of ...

The Austin sports medicine doctors at Medicine in Motion know firsthand what a marathon or long race can do to the body, so they've compiled a list of tips for post-race recovery.

Austin, Texas (PRWEB) February 05, 2013

1. Dont sit. Walk around for a few minutes to bring the heart rate down slowly and to avoid the risk of blood pooling in the legs.

2. Dry clothes. Once the body starts to slow down, those wet running clothes will start to feel uncomfortable and maybe give the chills. Change into something warm and soft. Also put on another pair of shoes that provide plenty of support.

3. Assess your pain levels. If in a lot of pain or just not feeling quite right, head to the medical tent immediately.

4. Drink. A combination of water and sports drinks will help replenish lost fluids, sodium and electrolytes.

5. Eat carbohydrates and proteins. Muscles need help repairing themselves after an intense run. A 3 to 1 ratio of carbs to protein can do the most good within 30 minutes after the event. The right balance of food can also help minimize sore muscles and stiffness.

6. Stretch. After a run, muscles are still warm and flexible theres no better time for a stretch just dont overdo it!

7. Avoid ibuprofen. Dont take anti-inflammatories immediately after the race if not well hydrated, they could damage the kidneys. Wait a few hours until the water has had a chance to rehydrate your system.

8. Ice packs/ice bath. An ice bath is an ideal way to reduce inflammation after a long run. If that doesnt sound appealing, opt for ice packs on the spots that are the sorest.

Read this article:

Austin Sports Medicine: Post-Race Recovery Tips from Medicine in Motion